Skip to main content

ino-5401

·Code: INO-5401, INO-9012

ino-5401: 3 clinical trials tracked.

ino-5401 evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about ino-5401, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 1 study sponsors
Clinical Trial Registry Records (3)

Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations

NCT04367675Registry updated 2026-08-14·Phase 1
Active, not recruiting

Primary endpoint: Dose Limiting Toxicities

Interventionalopen44 targetStarted 2021-04Completion 2027-031 site · United StatesAbramson Cancer Center at Penn Medicine

An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

NCT03502785Registry updated 2026-09-02·Phase 1/Phase 2·INO
Completed

Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs) Treatment

Interventionalopen35 enrolledStarted 2018-07Completion 2025-0511 sites · United StatesInovio Pharmaceuticals

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)

NCT03491683Registry updated 2026-03-19·Phase 1/Phase 2·INO

Primary endpoint: Percentage of Participants with Adverse Events (AEs)

Interventionalopen52 targetStarted 2018-05Completion 2026-1221 sites · United StatesInovio Pharmaceuticals